SCHEMBL5772506

SCHEMBL5772506

COCCNc1nccc(-c2[nH]c(C3OCC(C)(C(=O)NC4CC4)CO3)nc2-c2ccc(F)cc2)n1

nearest known ligand 0.82

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 12/20 0.82
MAPK13 O15264 11/20 0.82
MAPK12 P53778 11/20 0.82
MAPK11 Q15759 11/20 0.82
DYRK3 O43781 1/20 0.41
PRKD3 O94806 1/20 0.41
MAP4K4 O95819 1/20 0.41
FLT4 P35916 1/20 0.41
KDR P35968 1/20 0.41
MATK P42679 1/20 0.41
FRK P42685 1/20 0.41
MAPK9 P45984 1/20 0.41
CSNK1A1 P48729 1/20 0.41
CSNK1D P48730 1/20 0.41
CLK2 P49760 1/20 0.41
GSK3A P49840 1/20 0.41
GSK3B P49841 1/20 0.41
CSNK1G2 P78368 1/20 0.41
TAOK1 Q7L7X3 1/20 0.41
MINK1 Q8N4C8 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5796223 0.96 MAPK13 (0.79) MAPK14MAPK13MAPK12MAPK11DYRK3
SCHEMBL5771445 0.96 MAPK13 (0.85) MAPK14MAPK13MAPK12MAPK11
SCHEMBL5770147 0.93 MAPK13 (0.82) MAPK14MAPK13MAPK12MAPK11
SCHEMBL5768976 0.92 MAPK14 (0.76) MAPK14MAPK13MAPK12MAPK11
SCHEMBL5768242 0.92 MAPK13 (0.83) MAPK14MAPK13MAPK12MAPK11DYRK3
SCHEMBL5773247 0.92 MAPK14 (0.71) MAPK14MAPK13MAPK12MAPK11
SCHEMBL5769202 0.91 MAPK14 (0.70) MAPK14MAPK13MAPK12MAPK11
SCHEMBL5767969 0.91 MAPK14 (0.72) MAPK14MAPK13MAPK12MAPK11
SCHEMBL5768131 0.91 MAPK14 (0.69) MAPK14MAPK13MAPK12MAPK11
SCHEMBL5770449 0.90 MAPK14 (0.69) MAPK14MAPK13MAPK12MAPK11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0988301-B1 IMIDAZOLYL-CYCLIC ACETALS AVENTIS PHARMA LTD (GB) 2006-08-09 EP disclosed
US-6989395-B2 Imidazolyl-cyclic acetals AVENTIS PHARMA LIMITED (GB) 2006-01-24 US disclosed
US-20040038991-A1 Imidazolyl-cyclic acetals AVENTIS PHARMA LIMITED (GB) 2004-02-26 US disclosed
EP-0988301-A1 IMIDAZOLYL-CYCLIC ACETALS RHONE-POULENC RORER LIMITED (GB) 2000-03-29 EP disclosed
WO-1998056788-A1 IMIDAZOLYL-CYCLIC ACETALS RHONE-POULENC RORER LIMITED (GB) 1998-12-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040038991-A1 Imidazolyl-cyclic acetals CBR1, LBR, CBR3 MAPK14 1915/4885MAPK13 1610/4885MAPK12 2766/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.